Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma
Identifieur interne : 001132 ( Istex/Corpus ); précédent : 001131; suivant : 001133Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma
Auteurs : Makiko Hoshino ; Hiroyuki Kawashima ; Akira Ogose ; Naoko Kudo ; Takashi Ariizumi ; Tetsuo Hotta ; Hajime Umezu ; Hiroshi Hatano ; Tetsuro Morita ; Jyun Nishio ; Hiroshi Iwasaki ; Naoto EndoSource :
- Journal of Cancer Research and Clinical Oncology [ 0171-5216 ] ; 2010-03-01.
English descriptors
- KwdEn :
Abstract
Abstract: Purpose: We report here, our experience of seven patients with epithelioid sarcomas and their serum CA 125 levels, as well as the results of an in vitro and in vivo study of CA 125 expression in epithelioid sarcoma cells and xenografts using three epithelioid sarcoma cell lines. Methods: In the clinical study, the serum CA 125 levels of seven epithelioid sarcoma patients were examined at multiple time points. Expression of the MUC16 gene that encodes the CA 125 sequence was examined using RT-PCR methods in three epithelioid sarcoma cell lines, FU-EPS-1, SFT-8606 and NEPS, and the CA 125 protein in each cell lysate was examined by Western blot using anti-CA 125 clone OC125 antibody. The concentration of CA 125 in the conditioned medium of each cell line was also measured. Results: In five of the seven epithelioid sarcoma patients, CA 125 levels reflected regression and progression of their disease. The CA 125 concentrations in the conditioned medium of FU-EPS-1, SFT-8606 and NEPS cells were 259, 252, and 6 U/ml, respectively. Strong expression of MUC16 mRNA was shown in FU-EPS-1 and SFT-8606 cells: correspondingly, a thick band was observed by Western blot analysis in only FU-EPS-1 and SFT-8606 cells. Conclusion: We concluded that epithelioid sarcoma cells produce and secrete CA 125 into the blood serum and that the elevation of serum CA 125 correlates with disease progression. Therefore, measuring the serum CA 125 level should provide an useful index for diagnosing and monitoring the course of epithelioid sarcoma.
Url:
DOI: 10.1007/s00432-009-0678-1
Links to Exploration step
ISTEX:6B89052166E634F801F3620D76AA373F650FDCD1Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma</title><author><name sortKey="Hoshino, Makiko" sort="Hoshino, Makiko" uniqKey="Hoshino M" first="Makiko" last="Hoshino">Makiko Hoshino</name><affiliation><mods:affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kawashima, Hiroyuki" sort="Kawashima, Hiroyuki" uniqKey="Kawashima H" first="Hiroyuki" last="Kawashima">Hiroyuki Kawashima</name><affiliation><mods:affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: inskawa@med.niigata-u.ac.jp</mods:affiliation></affiliation></author><author><name sortKey="Ogose, Akira" sort="Ogose, Akira" uniqKey="Ogose A" first="Akira" last="Ogose">Akira Ogose</name><affiliation><mods:affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kudo, Naoko" sort="Kudo, Naoko" uniqKey="Kudo N" first="Naoko" last="Kudo">Naoko Kudo</name><affiliation><mods:affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</mods:affiliation></affiliation></author><author><name sortKey="Ariizumi, Takashi" sort="Ariizumi, Takashi" uniqKey="Ariizumi T" first="Takashi" last="Ariizumi">Takashi Ariizumi</name><affiliation><mods:affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</mods:affiliation></affiliation></author><author><name sortKey="Hotta, Tetsuo" sort="Hotta, Tetsuo" uniqKey="Hotta T" first="Tetsuo" last="Hotta">Tetsuo Hotta</name><affiliation><mods:affiliation>Department of Surgery, Niigata University Hospital, 1 Asahimachi-dori, Chuo-ku, 951-8520, Niigata, Japan</mods:affiliation></affiliation></author><author><name sortKey="Umezu, Hajime" sort="Umezu, Hajime" uniqKey="Umezu H" first="Hajime" last="Umezu">Hajime Umezu</name><affiliation><mods:affiliation>Department of Pathology, Niigata University Hospital, 1 Asahimachi-dori, Chuo-ku, 951-8520, Niigata, Japan</mods:affiliation></affiliation></author><author><name sortKey="Hatano, Hiroshi" sort="Hatano, Hiroshi" uniqKey="Hatano H" first="Hiroshi" last="Hatano">Hiroshi Hatano</name><affiliation><mods:affiliation>Department of Orthopedic Surgery, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, Chuo-ku, 951-8566, Niigata, Japan</mods:affiliation></affiliation></author><author><name sortKey="Morita, Tetsuro" sort="Morita, Tetsuro" uniqKey="Morita T" first="Tetsuro" last="Morita">Tetsuro Morita</name><affiliation><mods:affiliation>Department of Orthopedic Surgery, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, Chuo-ku, 951-8566, Niigata, Japan</mods:affiliation></affiliation></author><author><name sortKey="Nishio, Jyun" sort="Nishio, Jyun" uniqKey="Nishio J" first="Jyun" last="Nishio">Jyun Nishio</name><affiliation><mods:affiliation>Department of Orthopedic Surgery, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, 814-0180, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Iwasaki, Hiroshi" sort="Iwasaki, Hiroshi" uniqKey="Iwasaki H" first="Hiroshi" last="Iwasaki">Hiroshi Iwasaki</name><affiliation><mods:affiliation>Department of Pathology, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, 814-0180, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Endo, Naoto" sort="Endo, Naoto" uniqKey="Endo N" first="Naoto" last="Endo">Naoto Endo</name><affiliation><mods:affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6B89052166E634F801F3620D76AA373F650FDCD1</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1007/s00432-009-0678-1</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-911CRJCL-B/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001132</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001132</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma</title><author><name sortKey="Hoshino, Makiko" sort="Hoshino, Makiko" uniqKey="Hoshino M" first="Makiko" last="Hoshino">Makiko Hoshino</name><affiliation><mods:affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kawashima, Hiroyuki" sort="Kawashima, Hiroyuki" uniqKey="Kawashima H" first="Hiroyuki" last="Kawashima">Hiroyuki Kawashima</name><affiliation><mods:affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: inskawa@med.niigata-u.ac.jp</mods:affiliation></affiliation></author><author><name sortKey="Ogose, Akira" sort="Ogose, Akira" uniqKey="Ogose A" first="Akira" last="Ogose">Akira Ogose</name><affiliation><mods:affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kudo, Naoko" sort="Kudo, Naoko" uniqKey="Kudo N" first="Naoko" last="Kudo">Naoko Kudo</name><affiliation><mods:affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</mods:affiliation></affiliation></author><author><name sortKey="Ariizumi, Takashi" sort="Ariizumi, Takashi" uniqKey="Ariizumi T" first="Takashi" last="Ariizumi">Takashi Ariizumi</name><affiliation><mods:affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</mods:affiliation></affiliation></author><author><name sortKey="Hotta, Tetsuo" sort="Hotta, Tetsuo" uniqKey="Hotta T" first="Tetsuo" last="Hotta">Tetsuo Hotta</name><affiliation><mods:affiliation>Department of Surgery, Niigata University Hospital, 1 Asahimachi-dori, Chuo-ku, 951-8520, Niigata, Japan</mods:affiliation></affiliation></author><author><name sortKey="Umezu, Hajime" sort="Umezu, Hajime" uniqKey="Umezu H" first="Hajime" last="Umezu">Hajime Umezu</name><affiliation><mods:affiliation>Department of Pathology, Niigata University Hospital, 1 Asahimachi-dori, Chuo-ku, 951-8520, Niigata, Japan</mods:affiliation></affiliation></author><author><name sortKey="Hatano, Hiroshi" sort="Hatano, Hiroshi" uniqKey="Hatano H" first="Hiroshi" last="Hatano">Hiroshi Hatano</name><affiliation><mods:affiliation>Department of Orthopedic Surgery, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, Chuo-ku, 951-8566, Niigata, Japan</mods:affiliation></affiliation></author><author><name sortKey="Morita, Tetsuro" sort="Morita, Tetsuro" uniqKey="Morita T" first="Tetsuro" last="Morita">Tetsuro Morita</name><affiliation><mods:affiliation>Department of Orthopedic Surgery, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, Chuo-ku, 951-8566, Niigata, Japan</mods:affiliation></affiliation></author><author><name sortKey="Nishio, Jyun" sort="Nishio, Jyun" uniqKey="Nishio J" first="Jyun" last="Nishio">Jyun Nishio</name><affiliation><mods:affiliation>Department of Orthopedic Surgery, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, 814-0180, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Iwasaki, Hiroshi" sort="Iwasaki, Hiroshi" uniqKey="Iwasaki H" first="Hiroshi" last="Iwasaki">Hiroshi Iwasaki</name><affiliation><mods:affiliation>Department of Pathology, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, 814-0180, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Endo, Naoto" sort="Endo, Naoto" uniqKey="Endo N" first="Naoto" last="Endo">Naoto Endo</name><affiliation><mods:affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Cancer Research and Clinical Oncology</title><title level="j" type="abbrev">J Cancer Res Clin Oncol</title><idno type="ISSN">0171-5216</idno><idno type="eISSN">1432-1335</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="2010-03-01">2010-03-01</date><biblScope unit="volume">136</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="457">457</biblScope><biblScope unit="page" to="464">464</biblScope></imprint><idno type="ISSN">0171-5216</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0171-5216</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>CA 125</term><term>Epithelioid sarcoma</term><term>Production</term><term>Secretion</term><term>Tumor marker</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Purpose: We report here, our experience of seven patients with epithelioid sarcomas and their serum CA 125 levels, as well as the results of an in vitro and in vivo study of CA 125 expression in epithelioid sarcoma cells and xenografts using three epithelioid sarcoma cell lines. Methods: In the clinical study, the serum CA 125 levels of seven epithelioid sarcoma patients were examined at multiple time points. Expression of the MUC16 gene that encodes the CA 125 sequence was examined using RT-PCR methods in three epithelioid sarcoma cell lines, FU-EPS-1, SFT-8606 and NEPS, and the CA 125 protein in each cell lysate was examined by Western blot using anti-CA 125 clone OC125 antibody. The concentration of CA 125 in the conditioned medium of each cell line was also measured. Results: In five of the seven epithelioid sarcoma patients, CA 125 levels reflected regression and progression of their disease. The CA 125 concentrations in the conditioned medium of FU-EPS-1, SFT-8606 and NEPS cells were 259, 252, and 6 U/ml, respectively. Strong expression of MUC16 mRNA was shown in FU-EPS-1 and SFT-8606 cells: correspondingly, a thick band was observed by Western blot analysis in only FU-EPS-1 and SFT-8606 cells. Conclusion: We concluded that epithelioid sarcoma cells produce and secrete CA 125 into the blood serum and that the elevation of serum CA 125 correlates with disease progression. Therefore, measuring the serum CA 125 level should provide an useful index for diagnosing and monitoring the course of epithelioid sarcoma.</div></front></TEI><istex><corpusName>springer-journals</corpusName><author><json:item><name>Makiko Hoshino</name><affiliations><json:string>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</json:string></affiliations></json:item><json:item><name>Hiroyuki Kawashima</name><affiliations><json:string>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</json:string><json:string>E-mail: inskawa@med.niigata-u.ac.jp</json:string></affiliations></json:item><json:item><name>Akira Ogose</name><affiliations><json:string>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</json:string></affiliations></json:item><json:item><name>Naoko Kudo</name><affiliations><json:string>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</json:string></affiliations></json:item><json:item><name>Takashi Ariizumi</name><affiliations><json:string>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</json:string></affiliations></json:item><json:item><name>Tetsuo Hotta</name><affiliations><json:string>Department of Surgery, Niigata University Hospital, 1 Asahimachi-dori, Chuo-ku, 951-8520, Niigata, Japan</json:string></affiliations></json:item><json:item><name>Hajime Umezu</name><affiliations><json:string>Department of Pathology, Niigata University Hospital, 1 Asahimachi-dori, Chuo-ku, 951-8520, Niigata, Japan</json:string></affiliations></json:item><json:item><name>Hiroshi Hatano</name><affiliations><json:string>Department of Orthopedic Surgery, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, Chuo-ku, 951-8566, Niigata, Japan</json:string></affiliations></json:item><json:item><name>Tetsuro Morita</name><affiliations><json:string>Department of Orthopedic Surgery, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, Chuo-ku, 951-8566, Niigata, Japan</json:string></affiliations></json:item><json:item><name>Jyun Nishio</name><affiliations><json:string>Department of Orthopedic Surgery, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, 814-0180, Fukuoka, Japan</json:string></affiliations></json:item><json:item><name>Hiroshi Iwasaki</name><affiliations><json:string>Department of Pathology, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, 814-0180, Fukuoka, Japan</json:string></affiliations></json:item><json:item><name>Naoto Endo</name><affiliations><json:string>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>CA 125</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Epithelioid sarcoma</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Production</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Secretion</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Tumor marker</value></json:item></subject><articleId><json:string>678</json:string><json:string>s00432-009-0678-1</json:string></articleId><arkIstex>ark:/67375/VQC-911CRJCL-B</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>OriginalPaper</json:string></originalGenre><abstract>Abstract: Purpose: We report here, our experience of seven patients with epithelioid sarcomas and their serum CA 125 levels, as well as the results of an in vitro and in vivo study of CA 125 expression in epithelioid sarcoma cells and xenografts using three epithelioid sarcoma cell lines. Methods: In the clinical study, the serum CA 125 levels of seven epithelioid sarcoma patients were examined at multiple time points. Expression of the MUC16 gene that encodes the CA 125 sequence was examined using RT-PCR methods in three epithelioid sarcoma cell lines, FU-EPS-1, SFT-8606 and NEPS, and the CA 125 protein in each cell lysate was examined by Western blot using anti-CA 125 clone OC125 antibody. The concentration of CA 125 in the conditioned medium of each cell line was also measured. Results: In five of the seven epithelioid sarcoma patients, CA 125 levels reflected regression and progression of their disease. The CA 125 concentrations in the conditioned medium of FU-EPS-1, SFT-8606 and NEPS cells were 259, 252, and 6 U/ml, respectively. Strong expression of MUC16 mRNA was shown in FU-EPS-1 and SFT-8606 cells: correspondingly, a thick band was observed by Western blot analysis in only FU-EPS-1 and SFT-8606 cells. Conclusion: We concluded that epithelioid sarcoma cells produce and secrete CA 125 into the blood serum and that the elevation of serum CA 125 correlates with disease progression. Therefore, measuring the serum CA 125 level should provide an useful index for diagnosing and monitoring the course of epithelioid sarcoma.</abstract><qualityIndicators><score>9.394</score><pdfWordCount>4430</pdfWordCount><pdfCharCount>27180</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>8</pdfPageCount><pdfPageSize>595.276 x 790.866 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>247</abstractWordCount><abstractCharCount>1549</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma</title><genre><json:string>research-article</json:string></genre><host><title>Journal of Cancer Research and Clinical Oncology</title><language><json:string>unknown</json:string></language><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><issn><json:string>0171-5216</json:string></issn><eissn><json:string>1432-1335</json:string></eissn><journalId><json:string>432</json:string></journalId><volume>136</volume><issue>3</issue><pages><first>457</first><last>464</last></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Hematology</value></json:item><json:item><value>Internal Medicine</value></json:item><json:item><value>Cancer Research</value></json:item><json:item><value>Oncology</value></json:item></subject></host><ark><json:string>ark:/67375/VQC-911CRJCL-B</json:string></ark><publicationDate>2010</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1007/s00432-009-0678-1</json:string></doi><id>6B89052166E634F801F3620D76AA373F650FDCD1</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-911CRJCL-B/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-911CRJCL-B/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/VQC-911CRJCL-B/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><availability><licence><p>Springer-Verlag, 2009</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</p></availability><date>2009-03-21</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note>Original Paper</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma</title><author xml:id="author-0000"><persName><forename type="first">Makiko</forename><surname>Hoshino</surname></persName><affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</affiliation></author><author xml:id="author-0001" corresp="yes"><persName><forename type="first">Hiroyuki</forename><surname>Kawashima</surname></persName><email>inskawa@med.niigata-u.ac.jp</email><affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Akira</forename><surname>Ogose</surname></persName><affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Naoko</forename><surname>Kudo</surname></persName><affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Takashi</forename><surname>Ariizumi</surname></persName><affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Tetsuo</forename><surname>Hotta</surname></persName><affiliation>Department of Surgery, Niigata University Hospital, 1 Asahimachi-dori, Chuo-ku, 951-8520, Niigata, Japan</affiliation></author><author xml:id="author-0006"><persName><forename type="first">Hajime</forename><surname>Umezu</surname></persName><affiliation>Department of Pathology, Niigata University Hospital, 1 Asahimachi-dori, Chuo-ku, 951-8520, Niigata, Japan</affiliation></author><author xml:id="author-0007"><persName><forename type="first">Hiroshi</forename><surname>Hatano</surname></persName><affiliation>Department of Orthopedic Surgery, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, Chuo-ku, 951-8566, Niigata, Japan</affiliation></author><author xml:id="author-0008"><persName><forename type="first">Tetsuro</forename><surname>Morita</surname></persName><affiliation>Department of Orthopedic Surgery, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, Chuo-ku, 951-8566, Niigata, Japan</affiliation></author><author xml:id="author-0009"><persName><forename type="first">Jyun</forename><surname>Nishio</surname></persName><affiliation>Department of Orthopedic Surgery, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, 814-0180, Fukuoka, Japan</affiliation></author><author xml:id="author-0010"><persName><forename type="first">Hiroshi</forename><surname>Iwasaki</surname></persName><affiliation>Department of Pathology, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, 814-0180, Fukuoka, Japan</affiliation></author><author xml:id="author-0011"><persName><forename type="first">Naoto</forename><surname>Endo</surname></persName><affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</affiliation></author><idno type="istex">6B89052166E634F801F3620D76AA373F650FDCD1</idno><idno type="ark">ark:/67375/VQC-911CRJCL-B</idno><idno type="DOI">10.1007/s00432-009-0678-1</idno><idno type="article-id">678</idno><idno type="article-id">s00432-009-0678-1</idno></analytic><monogr><title level="j">Journal of Cancer Research and Clinical Oncology</title><title level="j" type="abbrev">J Cancer Res Clin Oncol</title><idno type="pISSN">0171-5216</idno><idno type="eISSN">1432-1335</idno><idno type="journal-ID">true</idno><idno type="issue-article-count">16</idno><idno type="volume-issue-count">12</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="2010-03-01"></date><biblScope unit="volume">136</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="457">457</biblScope><biblScope unit="page" to="464">464</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009-03-21</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Purpose: We report here, our experience of seven patients with epithelioid sarcomas and their serum CA 125 levels, as well as the results of an in vitro and in vivo study of CA 125 expression in epithelioid sarcoma cells and xenografts using three epithelioid sarcoma cell lines. Methods: In the clinical study, the serum CA 125 levels of seven epithelioid sarcoma patients were examined at multiple time points. Expression of the MUC16 gene that encodes the CA 125 sequence was examined using RT-PCR methods in three epithelioid sarcoma cell lines, FU-EPS-1, SFT-8606 and NEPS, and the CA 125 protein in each cell lysate was examined by Western blot using anti-CA 125 clone OC125 antibody. The concentration of CA 125 in the conditioned medium of each cell line was also measured. Results: In five of the seven epithelioid sarcoma patients, CA 125 levels reflected regression and progression of their disease. The CA 125 concentrations in the conditioned medium of FU-EPS-1, SFT-8606 and NEPS cells were 259, 252, and 6 U/ml, respectively. Strong expression of MUC16 mRNA was shown in FU-EPS-1 and SFT-8606 cells: correspondingly, a thick band was observed by Western blot analysis in only FU-EPS-1 and SFT-8606 cells. Conclusion: We concluded that epithelioid sarcoma cells produce and secrete CA 125 into the blood serum and that the elevation of serum CA 125 correlates with disease progression. Therefore, measuring the serum CA 125 level should provide an useful index for diagnosing and monitoring the course of epithelioid sarcoma.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>CA 125</term></item><item><term>Epithelioid sarcoma</term></item><item><term>Production</term></item><item><term>Secretion</term></item><item><term>Tumor marker</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Medicine & Public Health</head><item><term>Hematology</term></item><item><term>Internal Medicine</term></item><item><term>Cancer Research</term></item><item><term>Oncology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-03-21">Created</change><change when="2010-03-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-911CRJCL-B/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus springer-journals not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName><PublisherLocation>Berlin/Heidelberg</PublisherLocation></PublisherInfo><Journal OutputMedium="All"><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>432</JournalID><JournalPrintISSN>0171-5216</JournalPrintISSN><JournalElectronicISSN>1432-1335</JournalElectronicISSN><JournalTitle>Journal of Cancer Research and Clinical Oncology</JournalTitle><JournalAbbreviatedTitle>J Cancer Res Clin Oncol</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Medicine & Public Health</JournalSubject><JournalSubject Type="Secondary">Hematology</JournalSubject><JournalSubject Type="Secondary">Internal Medicine </JournalSubject><JournalSubject Type="Secondary">Cancer Research </JournalSubject><JournalSubject Type="Secondary">Oncology </JournalSubject></JournalSubjectGroup></JournalInfo><Volume OutputMedium="All"><VolumeInfo TocLevels="0" VolumeType="Regular"><VolumeIDStart>136</VolumeIDStart><VolumeIDEnd>136</VolumeIDEnd><VolumeIssueCount>12</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular" OutputMedium="All"><IssueInfo IssueType="Regular" TocLevels="0"><IssueIDStart>3</IssueIDStart><IssueIDEnd>3</IssueIDEnd><IssueArticleCount>16</IssueArticleCount><IssueHistory><OnlineDate><Year>2010</Year><Month>1</Month><Day>22</Day></OnlineDate><PrintDate><Year>2010</Year><Month>1</Month><Day>21</Day></PrintDate><CoverDate><Year>2010</Year><Month>3</Month></CoverDate><PricelistYear>2010</PricelistYear></IssueHistory><IssueCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>2010</CopyrightYear></IssueCopyright></IssueInfo><Article ID="s00432-009-0678-1" OutputMedium="All"><ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0"><ArticleID>678</ArticleID><ArticleDOI>10.1007/s00432-009-0678-1</ArticleDOI><ArticleSequenceNumber>14</ArticleSequenceNumber><ArticleTitle Language="En" OutputMedium="All">Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma</ArticleTitle><ArticleCategory>Original Paper</ArticleCategory><ArticleFirstPage>457</ArticleFirstPage><ArticleLastPage>464</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2009</Year><Month>8</Month><Day>24</Day></RegistrationDate><Received><Year>2009</Year><Month>3</Month><Day>21</Day></Received><Accepted><Year>2009</Year><Month>8</Month><Day>24</Day></Accepted><OnlineDate><Year>2009</Year><Month>9</Month><Day>16</Day></OnlineDate></ArticleHistory><ArticleCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>2009</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Makiko</GivenName><FamilyName>Hoshino</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Hiroyuki</GivenName><FamilyName>Kawashima</FamilyName></AuthorName><Contact><Phone>+81-25-2272272</Phone><Fax>+81-25-2270782</Fax><Email>inskawa@med.niigata-u.ac.jp</Email></Contact></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Akira</GivenName><FamilyName>Ogose</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Naoko</GivenName><FamilyName>Kudo</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Takashi</GivenName><FamilyName>Ariizumi</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Tetsuo</GivenName><FamilyName>Hotta</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff3"><AuthorName DisplayOrder="Western"><GivenName>Hajime</GivenName><FamilyName>Umezu</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff4"><AuthorName DisplayOrder="Western"><GivenName>Hiroshi</GivenName><FamilyName>Hatano</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff4"><AuthorName DisplayOrder="Western"><GivenName>Tetsuro</GivenName><FamilyName>Morita</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff5"><AuthorName DisplayOrder="Western"><GivenName>Jyun</GivenName><FamilyName>Nishio</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff6"><AuthorName DisplayOrder="Western"><GivenName>Hiroshi</GivenName><FamilyName>Iwasaki</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Naoto</GivenName><FamilyName>Endo</FamilyName></AuthorName></Author><Affiliation ID="Aff1"><OrgDivision>Division of Orthopedic Surgery</OrgDivision><OrgName>Niigata University Graduate School of Medical and Dental Sciences</OrgName><OrgAddress><Street>1 Asahimachi-dori, Chuo-ku</Street><City>Niigata</City><Postcode>951-8510</Postcode><Country Code="JP">Japan</Country></OrgAddress></Affiliation><Affiliation ID="Aff2"><OrgDivision>Department of Surgery</OrgDivision><OrgName>Niigata University Hospital</OrgName><OrgAddress><Street>1 Asahimachi-dori, Chuo-ku</Street><City>Niigata</City><Postcode>951-8520</Postcode><Country Code="JP">Japan</Country></OrgAddress></Affiliation><Affiliation ID="Aff3"><OrgDivision>Department of Pathology</OrgDivision><OrgName>Niigata University Hospital</OrgName><OrgAddress><Street>1 Asahimachi-dori, Chuo-ku</Street><City>Niigata</City><Postcode>951-8520</Postcode><Country Code="JP">Japan</Country></OrgAddress></Affiliation><Affiliation ID="Aff4"><OrgDivision>Department of Orthopedic Surgery</OrgDivision><OrgName>Niigata Cancer Center Hospital</OrgName><OrgAddress><Street>2-15-3 Kawagishi-cho, Chuo-ku</Street><City>Niigata</City><Postcode>951-8566</Postcode><Country Code="JP">Japan</Country></OrgAddress></Affiliation><Affiliation ID="Aff5"><OrgDivision>Department of Orthopedic Surgery</OrgDivision><OrgName>Fukuoka University School of Medicine</OrgName><OrgAddress><Street>7-45-1 Nanakuma, Jonan-ku</Street><City>Fukuoka</City><Postcode>814-0180</Postcode><Country Code="JP">Japan</Country></OrgAddress></Affiliation><Affiliation ID="Aff6"><OrgDivision>Department of Pathology</OrgDivision><OrgName>Fukuoka University School of Medicine</OrgName><OrgAddress><Street>7-45-1 Nanakuma, Jonan-ku</Street><City>Fukuoka</City><Postcode>814-0180</Postcode><Country Code="JP">Japan</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En" OutputMedium="All"><Heading>Abstract</Heading><AbstractSection ID="ASec1"><Heading>Purpose</Heading><Para>We report here, our experience of seven patients with epithelioid sarcomas and their serum CA 125 levels, as well as the results of an in vitro and in vivo study of CA 125 expression in epithelioid sarcoma cells and xenografts using three epithelioid sarcoma cell lines.</Para></AbstractSection><AbstractSection ID="ASec2"><Heading>Methods</Heading><Para>In the clinical study, the serum CA 125 levels of seven epithelioid sarcoma patients were examined at multiple time points. Expression of the MUC16 gene that encodes the CA 125 sequence was examined using RT-PCR methods in three epithelioid sarcoma cell lines, FU-EPS-1, SFT-8606 and NEPS, and the CA 125 protein in each cell lysate was examined by Western blot using anti-CA 125 clone OC125 antibody. The concentration of CA 125 in the conditioned medium of each cell line was also measured.</Para></AbstractSection><AbstractSection ID="ASec3"><Heading>Results</Heading><Para>In five of the seven epithelioid sarcoma patients, CA 125 levels reflected regression and progression of their disease. The CA 125 concentrations in the conditioned medium of FU-EPS-1, SFT-8606 and NEPS cells were 259, 252, and 6 U/ml, respectively. Strong expression of MUC16 mRNA was shown in FU-EPS-1 and SFT-8606 cells: correspondingly, a thick band was observed by Western blot analysis in only FU-EPS-1 and SFT-8606 cells.</Para></AbstractSection><AbstractSection ID="ASec4"><Heading>Conclusion</Heading><Para>We concluded that epithelioid sarcoma cells produce and secrete CA 125 into the blood serum and that the elevation of serum CA 125 correlates with disease progression. Therefore, measuring the serum CA 125 level should provide an useful index for diagnosing and monitoring the course of epithelioid sarcoma.</Para></AbstractSection></Abstract><KeywordGroup Language="En" OutputMedium="All"><Heading>Keywords</Heading><Keyword>CA 125</Keyword><Keyword>Epithelioid sarcoma</Keyword><Keyword>Production</Keyword><Keyword>Secretion</Keyword><Keyword>Tumor marker</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma</title></titleInfo><name type="personal"><namePart type="given">Makiko</namePart><namePart type="family">Hoshino</namePart><affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal" displayLabel="corresp"><namePart type="given">Hiroyuki</namePart><namePart type="family">Kawashima</namePart><affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</affiliation><affiliation>E-mail: inskawa@med.niigata-u.ac.jp</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Akira</namePart><namePart type="family">Ogose</namePart><affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Naoko</namePart><namePart type="family">Kudo</namePart><affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Takashi</namePart><namePart type="family">Ariizumi</namePart><affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tetsuo</namePart><namePart type="family">Hotta</namePart><affiliation>Department of Surgery, Niigata University Hospital, 1 Asahimachi-dori, Chuo-ku, 951-8520, Niigata, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hajime</namePart><namePart type="family">Umezu</namePart><affiliation>Department of Pathology, Niigata University Hospital, 1 Asahimachi-dori, Chuo-ku, 951-8520, Niigata, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hiroshi</namePart><namePart type="family">Hatano</namePart><affiliation>Department of Orthopedic Surgery, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, Chuo-ku, 951-8566, Niigata, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tetsuro</namePart><namePart type="family">Morita</namePart><affiliation>Department of Orthopedic Surgery, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, Chuo-ku, 951-8566, Niigata, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jyun</namePart><namePart type="family">Nishio</namePart><affiliation>Department of Orthopedic Surgery, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, 814-0180, Fukuoka, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hiroshi</namePart><namePart type="family">Iwasaki</namePart><affiliation>Department of Pathology, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, 814-0180, Fukuoka, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Naoto</namePart><namePart type="family">Endo</namePart><affiliation>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1 Asahimachi-dori, Chuo-ku, 951-8510, Niigata, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>Springer-Verlag</publisher><place><placeTerm type="text">Berlin/Heidelberg</placeTerm></place><dateCreated encoding="w3cdtf">2009-03-21</dateCreated><dateIssued encoding="w3cdtf">2010-03-01</dateIssued><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract lang="en">Abstract: Purpose: We report here, our experience of seven patients with epithelioid sarcomas and their serum CA 125 levels, as well as the results of an in vitro and in vivo study of CA 125 expression in epithelioid sarcoma cells and xenografts using three epithelioid sarcoma cell lines. Methods: In the clinical study, the serum CA 125 levels of seven epithelioid sarcoma patients were examined at multiple time points. Expression of the MUC16 gene that encodes the CA 125 sequence was examined using RT-PCR methods in three epithelioid sarcoma cell lines, FU-EPS-1, SFT-8606 and NEPS, and the CA 125 protein in each cell lysate was examined by Western blot using anti-CA 125 clone OC125 antibody. The concentration of CA 125 in the conditioned medium of each cell line was also measured. Results: In five of the seven epithelioid sarcoma patients, CA 125 levels reflected regression and progression of their disease. The CA 125 concentrations in the conditioned medium of FU-EPS-1, SFT-8606 and NEPS cells were 259, 252, and 6 U/ml, respectively. Strong expression of MUC16 mRNA was shown in FU-EPS-1 and SFT-8606 cells: correspondingly, a thick band was observed by Western blot analysis in only FU-EPS-1 and SFT-8606 cells. Conclusion: We concluded that epithelioid sarcoma cells produce and secrete CA 125 into the blood serum and that the elevation of serum CA 125 correlates with disease progression. Therefore, measuring the serum CA 125 level should provide an useful index for diagnosing and monitoring the course of epithelioid sarcoma.</abstract><note>Original Paper</note><subject lang="en"><genre>Keywords</genre><topic>CA 125</topic><topic>Epithelioid sarcoma</topic><topic>Production</topic><topic>Secretion</topic><topic>Tumor marker</topic></subject><relatedItem type="host"><titleInfo><title>Journal of Cancer Research and Clinical Oncology</title></titleInfo><titleInfo type="abbreviated"><title>J Cancer Res Clin Oncol</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>Springer</publisher><dateIssued encoding="w3cdtf">2010-01-22</dateIssued><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><subject><genre>Medicine & Public Health</genre><topic>Hematology</topic><topic>Internal Medicine</topic><topic>Cancer Research</topic><topic>Oncology</topic></subject><identifier type="ISSN">0171-5216</identifier><identifier type="eISSN">1432-1335</identifier><identifier type="JournalID">432</identifier><identifier type="IssueArticleCount">16</identifier><identifier type="VolumeIssueCount">12</identifier><part><date>2010</date><detail type="volume"><number>136</number><caption>vol.</caption></detail><detail type="issue"><number>3</number><caption>no.</caption></detail><extent unit="pages"><start>457</start><end>464</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 2010</recordOrigin></recordInfo></relatedItem><identifier type="istex">6B89052166E634F801F3620D76AA373F650FDCD1</identifier><identifier type="ark">ark:/67375/VQC-911CRJCL-B</identifier><identifier type="DOI">10.1007/s00432-009-0678-1</identifier><identifier type="ArticleID">678</identifier><identifier type="ArticleID">s00432-009-0678-1</identifier><accessCondition type="use and reproduction" contentType="copyright">Springer-Verlag, 2009</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</recordContentSource><recordOrigin>Springer-Verlag, 2009</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-911CRJCL-B/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001132 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001132 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:6B89052166E634F801F3620D76AA373F650FDCD1
|texte= Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma
}}
| This area was generated with Dilib version V0.6.33. |  |